Quantitative BioSciences, Inc.

Quantitative BioSciences, Inc. (QBI) is a biotechnology company that integrates bioengineering, synthetic biology, and bioinformatics to develop custom biosensing and immunoassay solutions. Founded in 2010, the company built the Qube platform, an at-line, autonomous sensing system designed for continuous, multiplexed, and quantitative monitoring of various analytes, including proteins, pathogens, chemicals, and environmental contaminants. Their technology utilizes proprietary synthetic libraries for rapid VHH (single-domain antibody) discovery, allowing for the customization of sensors to specific targets. The company combines microfluidics, machine learning, and advanced optics to translate biological signals into actionable data, providing alternatives to traditional, sporadic laboratory sampling methods.

QBI serves clients across the life sciences, pharmaceutical, water treatment, and environmental monitoring sectors by providing tools for process control, real-time quality assurance, and early warning systems. Their technology has been validated through numerous R&D projects supported by federal agencies including the NIH, DOE, DARPA, IARPA, USDA, EPA, and NOAA. By deploying these robust, field-deployable platforms, QBI helps partners reduce labor, automate complex monitoring workflows, and improve decision-making in both industrial and environmental settings. The company frequently collaborates with academic and commercial partners to demonstrate the utility and field robustness of its sensing technologies.